Today: 20 May 2026
BitMine Immersion Technologies (BMNR) stock slips today as new proxy filing spotlights its giant Ethereum stash
1 January 2026
2 mins read

BitMine Immersion Technologies (BMNR) stock slips today as new proxy filing spotlights its giant Ethereum stash

NEW YORK, December 31, 2025, 17:57 ET — After-hours

  • BitMine Immersion shares were down about 2% at $27.15 in after-hours trading.
  • An additional proxy filing showed a fresh push to lock in votes ahead of the company’s January 15 annual meeting.
  • Crypto prices were mixed, with ether near $2,972 and bitcoin lower, keeping crypto-linked equities in focus into year-end.

Shares of BitMine Immersion Technologies, Inc. fell about 2% in after-hours trading on Wednesday, tracking a volatile session as investors digested the company’s latest proxy-vote push ahead of a January shareholder meeting.

The timing matters because BitMine has repositioned itself as a corporate holder of crypto — especially ether — and shareholder approval of its meeting items could affect how aggressively it can raise capital.

BMNR has also traded as a high-beta proxy for crypto prices into the final week of the year, when liquidity can thin and moves can get exaggerated. Ether was up slightly on the day while bitcoin slipped.

As of 5:57 p.m. ET, BMNR was down $0.55 at $27.15. The stock traded between $26.86 and $28.22 during the session, with volume of about 33.6 million shares, market data showed.

In an additional proxy filing, the company included a text-message script from proxy solicitor Alliance Advisors urging shareholders to “VOTE YOUR SHARES TODAY!” and linking to a video message from chairman Tom Lee.

BitMine is seeking votes on four proposals at its January 15 annual meeting, including a charter amendment to increase the number of authorized common shares and approval of a 2025 omnibus incentive plan, the company said. It also put a non-binding advisory vote on a performance-based compensation arrangement for the executive chairman on the agenda.

The company’s vote campaign comes as it highlights the size of its crypto treasury. In a December 29 press release filed with the SEC, BitMine said its crypto, cash and other holdings totaled about $13.2 billion as of December 28, including 4.11 million ether tokens and $1.0 billion in cash, plus 192 bitcoin, using prices sourced from Coinbase.

BitMine also said the ether position represented 3.41% of Ethereum’s token supply. The company said it had staked 408,627 ether — locking up tokens to help validate transactions on the network in return for rewards — and was working toward launching its “Made in America Validator Network” staking solution in early 2026. SEC

Using the company’s cited composite Ethereum staking rate of 2.81%, fully staking 4.11 million ether would imply roughly 115,000 ether of annual rewards. At Wednesday’s ether price of about $2,972, that works out to about $343 million a year, before fees and execution risk.

“Year-end tax-loss related selling is pushing down crypto and crypto equity prices,” Lee said in the company’s release, pointing to the post-Christmas window as the heaviest period. SEC

Crypto-linked equities often trade off reference points set by large treasury-style holders. BitMine has pointed to Strategy Inc. (MSTR) — known for its bitcoin-heavy balance sheet — as the larger “global treasury,” framing itself as the ether-focused counterpart, according to the release. SEC

What investors will watch next is straightforward: the voting deadline, which the company’s chairman said is January 14 at 11:59 p.m. ET, and whether shareholders back the proposals that could expand the share count. Traders will also keep an eye on crypto prices and whether BMNR holds above Wednesday’s $26.86 low or reclaims the $28.22 session high.

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
AI stocks today: Nvidia, AMD tick higher as year-end trade turns cautious
Previous Story

AI stocks today: Nvidia, AMD tick higher as year-end trade turns cautious

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop